Table 1 Baseline sociodemographic, clinical, functional, radiologic characteristics of the patients
Variables | N = 79 |
|---|---|
Sociodemographic | |
Women, n (%) | 53 (79) |
Mean age at ILD diagnosis ± SD, years | 66.5 ± 11 |
Smokers (active and formers), n (%) | 11 (14) |
BMI, median [p25-75] | 26.5 [24–31.5] |
Hospital center, n (%) | |
FJD | 34 (43) |
HCSC | 23 (29) |
HiLe | 6 (7, 6) |
HIS | 2 (2, 5) |
HPH | 4 (5) |
HUG | 6 (7.6) |
HULP | 4 (5.1) |
Comorbidity n (%) (n = 74) | |
Total | 51 (68.9) |
Comorbidity, n (%) (n = 74) | |
Hypertension | 27 (36.5) |
Cholesterol | 22 (29.7) |
Diabetes Mellitus | 5 (6.7) |
Ischemic heart disease | 9 (12.2) |
Cerebrovascular disease | 4 (5.4) |
Peripheral vascular disease | 2 (2.7) |
Hypothyroidism | 9 (12.2) |
Liver disease | 4 (5.4) |
History of cancer | 7 (9.5) |
COPD-Bronchiectasis | 8 (10.8) |
Renal failure (dialysis) | 2 (2.7) |
GER | 4 (5.4) |
History of cancer | 7 (9.5) |
ILD associated (HRCT), n (%) | |
Fibrotic (n = 54) | 23 (42.6) |
Emphysema (n = 54) | 10 (18.5) |
PHT (n = 63) | 5 (8) |
PTF parameters, median [p25–75] | |
FVC% (n = 79) | 88 [74–101] |
DLCO% (n = 68) | 64 [50–81.5] |
Radiographic ILD pattern (HRCT) n (%) | |
UIP | 29 (36.7) |
NSIP | 37 (46.8) |
Others | 13 (16.5) |
Laboratory, median [p25–75] | |
ESR | 34 [17–50] |
Therapy previous IPAF, n (%) | |
Glucocorticoids -DAMRDs | 26 (33) |
Regimen of therapy during the follow-up, n (%) | |
None | 18 (22.7) |
Glucocorticoids and/or DMARDs and/or Anti-Fibrotic | 61 (77.2) |
Glucocorticoids alone | 5 (6.3) |
DMARDs and/or Anti-Fibrotic | 9 (11.5) |
Glucocorticoids and DMARDs and/or Anti-Fibrotic | 47 (59.5) |